Effects of EPO on blood parameters and running performance in Kenyan athletes

Diresibachew W Haile, Jérôme Durussel, Wondyefraw Mekonen, Neford Ongaro, Edwin Anjila, Martin Mooses, Evangelia Daskalaki, Kerli Mooses, John D. McClure, Shaun Sutehall, Yannis P. Pitsiladis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Recombinant human erythropoietin (rHuEpo) administration enhances oxygen carrying capacity and performance at sea level. It remains unknown whether similar effects would be observed in chronic altitude-adapted endurance runners. The aim of this study was to assess the effects of rHuEpo on hematological and performance parameters in chronic altitude-adapted endurance runners as compared to sea level athletes. Methods: Twenty well-trained Kenyan endurance runners (KEN) living and training at approximately 2150 m received rHuEpo injections of 50 IU·kg−1 body mass every 2 d for 4 wk and responses compared with another cohort (SCO) that underwent an identical protocol at sea level. Blood samples were obtained at baseline, during rHuEpo administration and 4 wk after the final injection. A maximal oxygen uptake (V˙O2max) test and 3000-m time trial was performed before, immediately after and 4 wk after the final rHuEpo injection. Results: Hematocrit (HCT) and hemoglobin concentration (HGB) were higher in KEN compared to SCO before rHuEpo but similar at the end of administration. Before rHuEpo administration, KEN had higher V˙O2max and faster time trial performance compared to SCO. After rHuEpo administration, there was a similar increase in V˙O2max and time trial performance in both cohorts; most effects of rHuEpo were maintained 4 wk after the final rHuEpo injection in both cohorts. Conclusions: Four weeks of rHuEpo increased the HGB and HCT of Kenyan endurance runners to a lesser extent than in SCO (~17% vs ~10%, respectively) and these alterations were associated with similar improvements in running performance immediately after the rHuEpo administration (~5%) and 4 wk after rHuEpo (~3%).
LanguageEnglish
Pages299–307
Number of pages9
JournalMedicine and Science in Sports and Exercise
Volume51
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Erythropoietin
Running
Athletes
Oceans and Seas
Injections
Hematocrit
Hemoglobins
Oxygen
Conservation of Natural Resources

Keywords

  • endurance performance
  • doping
  • chronic altitude exposure
  • East Africa

Cite this

Haile, D. W., Durussel, J., Mekonen, W., Ongaro, N., Anjila, E., Mooses, M., ... Pitsiladis, Y. P. (2019). Effects of EPO on blood parameters and running performance in Kenyan athletes. Medicine and Science in Sports and Exercise, 51(2), 299–307. https://doi.org/10.1249/MSS.0000000000001777
Haile, Diresibachew W ; Durussel, Jérôme ; Mekonen, Wondyefraw ; Ongaro, Neford ; Anjila, Edwin ; Mooses, Martin ; Daskalaki, Evangelia ; Mooses, Kerli ; McClure, John D. ; Sutehall, Shaun ; Pitsiladis, Yannis P. . / Effects of EPO on blood parameters and running performance in Kenyan athletes. In: Medicine and Science in Sports and Exercise. 2019 ; Vol. 51, No. 2. pp. 299–307.
@article{14e27a031e244feba0bac48ef164495e,
title = "Effects of EPO on blood parameters and running performance in Kenyan athletes",
abstract = "Introduction: Recombinant human erythropoietin (rHuEpo) administration enhances oxygen carrying capacity and performance at sea level. It remains unknown whether similar effects would be observed in chronic altitude-adapted endurance runners. The aim of this study was to assess the effects of rHuEpo on hematological and performance parameters in chronic altitude-adapted endurance runners as compared to sea level athletes. Methods: Twenty well-trained Kenyan endurance runners (KEN) living and training at approximately 2150 m received rHuEpo injections of 50 IU·kg−1 body mass every 2 d for 4 wk and responses compared with another cohort (SCO) that underwent an identical protocol at sea level. Blood samples were obtained at baseline, during rHuEpo administration and 4 wk after the final injection. A maximal oxygen uptake (V˙O2max) test and 3000-m time trial was performed before, immediately after and 4 wk after the final rHuEpo injection. Results: Hematocrit (HCT) and hemoglobin concentration (HGB) were higher in KEN compared to SCO before rHuEpo but similar at the end of administration. Before rHuEpo administration, KEN had higher V˙O2max and faster time trial performance compared to SCO. After rHuEpo administration, there was a similar increase in V˙O2max and time trial performance in both cohorts; most effects of rHuEpo were maintained 4 wk after the final rHuEpo injection in both cohorts. Conclusions: Four weeks of rHuEpo increased the HGB and HCT of Kenyan endurance runners to a lesser extent than in SCO (~17{\%} vs ~10{\%}, respectively) and these alterations were associated with similar improvements in running performance immediately after the rHuEpo administration (~5{\%}) and 4 wk after rHuEpo (~3{\%}).",
keywords = "endurance performance, doping, chronic altitude exposure, East Africa",
author = "Haile, {Diresibachew W} and J{\'e}r{\^o}me Durussel and Wondyefraw Mekonen and Neford Ongaro and Edwin Anjila and Martin Mooses and Evangelia Daskalaki and Kerli Mooses and McClure, {John D.} and Shaun Sutehall and Pitsiladis, {Yannis P.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1249/MSS.0000000000001777",
language = "English",
volume = "51",
pages = "299–307",
journal = "Medicine and Science in Sports and Exercise",
issn = "0195-9131",
number = "2",

}

Haile, DW, Durussel, J, Mekonen, W, Ongaro, N, Anjila, E, Mooses, M, Daskalaki, E, Mooses, K, McClure, JD, Sutehall, S & Pitsiladis, YP 2019, 'Effects of EPO on blood parameters and running performance in Kenyan athletes' Medicine and Science in Sports and Exercise, vol. 51, no. 2, pp. 299–307. https://doi.org/10.1249/MSS.0000000000001777

Effects of EPO on blood parameters and running performance in Kenyan athletes. / Haile, Diresibachew W; Durussel, Jérôme; Mekonen, Wondyefraw; Ongaro, Neford; Anjila, Edwin; Mooses, Martin; Daskalaki, Evangelia; Mooses, Kerli; McClure, John D.; Sutehall, Shaun; Pitsiladis, Yannis P. .

In: Medicine and Science in Sports and Exercise, Vol. 51, No. 2, 01.02.2019, p. 299–307.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of EPO on blood parameters and running performance in Kenyan athletes

AU - Haile, Diresibachew W

AU - Durussel, Jérôme

AU - Mekonen, Wondyefraw

AU - Ongaro, Neford

AU - Anjila, Edwin

AU - Mooses, Martin

AU - Daskalaki, Evangelia

AU - Mooses, Kerli

AU - McClure, John D.

AU - Sutehall, Shaun

AU - Pitsiladis, Yannis P.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: Recombinant human erythropoietin (rHuEpo) administration enhances oxygen carrying capacity and performance at sea level. It remains unknown whether similar effects would be observed in chronic altitude-adapted endurance runners. The aim of this study was to assess the effects of rHuEpo on hematological and performance parameters in chronic altitude-adapted endurance runners as compared to sea level athletes. Methods: Twenty well-trained Kenyan endurance runners (KEN) living and training at approximately 2150 m received rHuEpo injections of 50 IU·kg−1 body mass every 2 d for 4 wk and responses compared with another cohort (SCO) that underwent an identical protocol at sea level. Blood samples were obtained at baseline, during rHuEpo administration and 4 wk after the final injection. A maximal oxygen uptake (V˙O2max) test and 3000-m time trial was performed before, immediately after and 4 wk after the final rHuEpo injection. Results: Hematocrit (HCT) and hemoglobin concentration (HGB) were higher in KEN compared to SCO before rHuEpo but similar at the end of administration. Before rHuEpo administration, KEN had higher V˙O2max and faster time trial performance compared to SCO. After rHuEpo administration, there was a similar increase in V˙O2max and time trial performance in both cohorts; most effects of rHuEpo were maintained 4 wk after the final rHuEpo injection in both cohorts. Conclusions: Four weeks of rHuEpo increased the HGB and HCT of Kenyan endurance runners to a lesser extent than in SCO (~17% vs ~10%, respectively) and these alterations were associated with similar improvements in running performance immediately after the rHuEpo administration (~5%) and 4 wk after rHuEpo (~3%).

AB - Introduction: Recombinant human erythropoietin (rHuEpo) administration enhances oxygen carrying capacity and performance at sea level. It remains unknown whether similar effects would be observed in chronic altitude-adapted endurance runners. The aim of this study was to assess the effects of rHuEpo on hematological and performance parameters in chronic altitude-adapted endurance runners as compared to sea level athletes. Methods: Twenty well-trained Kenyan endurance runners (KEN) living and training at approximately 2150 m received rHuEpo injections of 50 IU·kg−1 body mass every 2 d for 4 wk and responses compared with another cohort (SCO) that underwent an identical protocol at sea level. Blood samples were obtained at baseline, during rHuEpo administration and 4 wk after the final injection. A maximal oxygen uptake (V˙O2max) test and 3000-m time trial was performed before, immediately after and 4 wk after the final rHuEpo injection. Results: Hematocrit (HCT) and hemoglobin concentration (HGB) were higher in KEN compared to SCO before rHuEpo but similar at the end of administration. Before rHuEpo administration, KEN had higher V˙O2max and faster time trial performance compared to SCO. After rHuEpo administration, there was a similar increase in V˙O2max and time trial performance in both cohorts; most effects of rHuEpo were maintained 4 wk after the final rHuEpo injection in both cohorts. Conclusions: Four weeks of rHuEpo increased the HGB and HCT of Kenyan endurance runners to a lesser extent than in SCO (~17% vs ~10%, respectively) and these alterations were associated with similar improvements in running performance immediately after the rHuEpo administration (~5%) and 4 wk after rHuEpo (~3%).

KW - endurance performance

KW - doping

KW - chronic altitude exposure

KW - East Africa

U2 - 10.1249/MSS.0000000000001777

DO - 10.1249/MSS.0000000000001777

M3 - Article

VL - 51

SP - 299

EP - 307

JO - Medicine and Science in Sports and Exercise

T2 - Medicine and Science in Sports and Exercise

JF - Medicine and Science in Sports and Exercise

SN - 0195-9131

IS - 2

ER -